Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants

被引：6

作者：

Strein, Micheal ^{[1
]}

May, Scott ^{[2
,3
]}

Brophy, Gretchen M. ^{[1
]}

机构：

[1] Virginia Commonwealth Univ, Sch Pharm, Richmond, VA USA

[2] Connecticut Childrens Med Ctr, Dept Pharm, Hartford, CT USA

[3] St Francis Hosp & Med Ctr, Dept Pharm, Hartford, CT USA

来源：

CURRENT OPINION IN CRITICAL CARE | 2020年 / 26卷 / 02期

关键词：

bleeding; anticoagulant; direct oral anticoagulant; intracranial hemorrhage; reversal; PROTHROMBIN COMPLEX CONCENTRATE; ACTIVATED FACTOR-VII; VITAMIN-K ANTAGONIST; FACTOR XA INHIBITOR; INTRACEREBRAL HEMORRHAGE; ATRIAL-FIBRILLATION; RABBIT MODEL; HEMOSTATIC THERAPY; ANDEXANET ALPHA; RIVAROXABAN;

D O I：

10.1097/MCC.0000000000000706

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Purpose of review This review focuses on recent relevant literature that examines the reversal of direct oral anticoagulants (DOACs) in patients with intracranial hemorrhage (ICH). The aim of this review is to provide an insightful description of available reversal agents and their clinical utility. Recent findings Increases in prescribing of DOACs has led to the introduction of drug-specific reversal agents. The clinical trials that evaluated these agents did not include a comparator arm making it difficult to determine if they are clinically superior to nonspecific reversal agents. Numerous options for reversal of DOAC-associated ICH are currently available. Recent clinical trials have demonstrated drug-specific reversal agents are effective in this setting, but additional research is needed to determine whether these agents should be routinely preferred over nonspecific reversal agents.

引用

页码：122 / 128

页数：7

共 66 条

[11] Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors [J].

Connolly, S. J. ;

Crowther, M. ;

Eikelboom, J. W. ;

Gibson, C. M. ;

Curnutte, J. T. ;

Lawrence, J. H. ;

Yue, P. ;

Bronson, M. D. ;

Lu, G. ;

Conley, P. B. ;

Verhamme, P. ;

Schmidt, J. ;

Middeldorp, S. ;

Cohen, A. T. ;

Beyer-Westendorf, J. ;

Albaladejo, P. ;

Lopez-Sendon, J. ;

Demchuk, A. M. ;

Pallin, D. J. ;

Concha, M. ;

Goodman, S. ;

Leeds, J. ;

Souza, S. ;

Siegal, D. M. ;

Zotova, E. ;

Meeks, B. ;

Ahmad, S. ;

Nakamya, J. ;

Milling, T. J., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (14) :1326-1335

[12] Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors [J].

Connolly, Stuart J. ;

Milling, Truman J., Jr. ;

Eikelboom, John W. ;

Gibson, C. Michael ;

Curnutte, John T. ;

Gold, Alex ;

Bronson, Michele D. ;

Lu, Genmin ;

Conley, Pamela B. ;

Verhamme, Peter ;

Schmidt, Jeannot ;

Middeldorp, Saskia ;

Cohen, Alexander T. ;

Beyer-Westendorf, Jan ;

Albaladejo, Pierre ;

Lopez-Sendon, Jose ;

Goodman, Shelly ;

Leeds, Janet ;

Wiens, Brian L. ;

Siegal, Deborah M. ;

Zotova, Elena ;

Meeks, Brandi ;

Nakamya, Juliet ;

Lim, W. Ting ;

Crowther, Mark .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (12) :1131-1141

[13] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[14] Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know [J].

Conway, Susan E. ;

Hwang, Andrew Y. ;

Ponte, Charles D. ;

Gums, John G. .

PHARMACOTHERAPY, 2017, 37 (02) :236-248

[15]

Daiichi Sankyo Inc., SAV ED PACK INS

[16] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN OBESE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: ARISTOPHANES SUBGROUP ANALYSIS [J].

Deitelzweig, Steven ;

Keshishian, Allison ;

Kang, Amiee ;

Dhamane, Amol ;

Luo, Xuemei ;

Li, Xiaoyan ;

Balachander, Neeraja ;

Rosenblatt, Lisa ;

Mardekian, Jack ;

Pan, Xianying ;

Di Fusco, Manuela ;

Garcia, Alessandra Bassalobre ;

Yuce, Huseyin ;

Lip, Gregory Y. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) :435-435

[17] A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation [J].

Feldberg, Jordanne ;

Patel, Param ;

Farrell, Ashley ;

Sivarajahkumar, Sylvia ;

Cameron, Karen ;

Ma, Jennifer ;

Battistella, Marisa .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (02) :265-277

[18]

Franchini M, 2010, BLOOD TRANSFUS-ITALY, V8, P149, DOI [10.2450/2010-0149-09, 10.2450/2010.0149-09]

[19]

Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x

[20] Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents [J].

Fukuda, Toshio ;

Honda, Yuko ;

Kamisato, Chikako ;

Morishima, Yoshiyuki ;

Shibano, Toshiro .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :253-259

← 1 2 3 4 5 6 7 →